Clinical Trials

Find a Clinical Trial

Enrolling Trials

31-40  of  92  for  "cancer"
►
EA9181, A Phase III Randomized Trial of Steroids+Tyrosine Kinase Inhibitor Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Abdelhadi, Kareem H
Blood - ALL - Acute Lymphocyctic
Adult
This phase III trial compares the effect of the combination of steroids, potent tyrosine kinase inhibitors (TKI), and blinatumomab versus treatment with steroids, TKI, and chemotherapy. The usual approach for the treatment of acute lymphoblastic leukemia (ALL) is chemotherapy, monoclonal antibodies, or targeted therapies that kill leukemia cells. These treatments are effective and typically control the ALL for a number of years, but are not curative and usually require chronic, indefinite treatment. Anti-inflammatory drugs, such as dexamethasone and prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Methotrexate may slow the growth of cancer cells. Ponatinib and dasatinib and may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as cyclophosphamide, doxorubicin, vincristine, and cytarabine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The information gained from this study may help researchers to compare overall survival following the study approach with steroids, TKI, and blinatumomab versus the usual approach.
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
S1608, Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Edmund, Joseph
Lymph Gland - Non-Hodgkin's
Other Blood Cancers - Non-Hodgkin's
Adult
This randomized phase II trial studies how well obinutuzumab with or without PI3K-delta inhibitor TGR-1202, lenalidomide, or combination chemotherapy work in treating patients with grade I-IIIa follicular lymphoma that has come back or does not respond to treatment. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. PI3K-delta inhibitor TGR-1202 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving obinutuzumab with or without PI3K-delta inhibitor TGR-1202, lenalidomide, or combination chemotherapy will work better in treating patients with grade I-IIIa follicular lymphoma.
Wilson, Anna E
(715) 858-6860
Wilson, Anna E
(715) 858-6860
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
MMC - Eau Claire
2116 Craig Rd
Eau Claire, WI  54701
MMC - Eau Claire
2116 Craig Rd
Eau Claire, WI  54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI  54848
MMC - Ladysmith
906 College Ave W
Ladysmith, WI  54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
NRG-GY019, A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Gokalp Yasar, Demet
Ovaries, Uterus, Cervix - Ovaries
Adult
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving letrozole alone or in combination with paclitaxel and carboplatin works better in treating patients with low-grade serous carcinoma of the ovary or peritoneum compared to paclitaxel and carboplatin without letrozole.
Craig, Chani L
(715) 358-1838
Diagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI  54476
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
EA8211-Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)
Bauer, Anderson
Bladder, Prostate, Kidney - Renal
Adult
This phase III trial compares the effect of stero-ablative radiotherapy (SAbR) followed by standard of care systemic therapy, to standard of care systemic therapy alone, in patients with kidney cancer that has spread from where it first started (primary site) to a limited (2-5) number of places in the body (metastatic). Study doctors want to find out if this approach is better or worse than the usual approach for metastatic kidney cancer. The usual approach is defined as the care most people get for metastatic kidney cancer which includes systemic therapy such as immunotherapy (given through the veins) and/or small molecular inhibitor (tablets taken by mouth). Radiotherapy uses high energy x-rays to kill cancer cells and shrink tumors. SAbR uses special equipment to position a patient and deliver radiation to tumors with high precision. Giving SAbR prior to systemic therapy may kill more tumor cells than the usual approach, which is systemic therapy alone.
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Rice Lake
2501 Main
Stevens Point, WI  54481
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Gokalp Yasar, Demet
Breast - Breast
Adult
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
Craig, Chani L
(715) 358-1838
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
MMC - Eau Claire
2116 Craig Rd
Eau Claire, WI  54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI  54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
NRG-GU010-Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Onitilo, Adedayo A
Bladder, Prostate, Kidney - Prostate
Adult
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness. The Decipher risk score evaluates a prostate cancer tumor for its potential for spreading. In patients with low risk scores, this trial compares radiation therapy alone to the usual treatment of radiation therapy and hormone therapy (androgen deprivation therapy). Radiation therapy uses high energy x-rays or particles to kill tumor cells and shrink tumors. Androgen deprivation therapy blocks the production or interferes with the action of male sex hormones such as testosterone, which plays a role in prostate cancer development. Giving radiation treatment alone may be the same as the usual approach in controlling the cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy. In patients with higher Decipher gene risk, this trial compares the addition of darolutamide to usual treatment radiation therapy and hormone therapy, to usual treatment. Darolutamide blocks the actions of the androgens (e.g. testosterone) in the tumor cells and in the body. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading.
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MMC - Eau Claire
2116 Craig Rd
Eau Claire, WI  54701
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Rice Lake
2501 Main
Stevens Point, WI  54481
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
AHOD2131-A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno- Oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Brandt, Jon
Lymph Gland - Hodgkin's
Child, Adult
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment (chemotherapy with or without radiation) alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine, and procarbazine hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Adding immunotherapy to the standard treatment of chemotherapy with or without radiation may increase survival in patients with classical Hodgkin lymphoma compared to the standard treatment alone.
Wolf, Terri L
(715) 387-9316
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Brandt, Jon
Lymph Gland
Child
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nivolumab with chemo-immunotherapy may help treat patients with PMBCL.
Welter, Stacy L
(715) 221-6492
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
NHLBI-MDS,The National Myelodysplastic Syndromes Natural History Study
Onitilo, Adedayo A
Other Blood Cancers - Myelodysplastic Syndrome
Adult
Multi-center study enrolling patients suspected or newly diagnosed with myelodysplastic syndromes (MDS), myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) overlap disorder, or idiopathic cytopenia of undetermined significance (ICUS). Participants will be followed long term. Clinical data, blood, and tissue samples will be collected to establish a biorepository to facilitate the study of the natural history of MDS.
Bulgrin, Angela M
(715) 221-7261
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MMC - Eau Claire
2116 Craig Rd
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
EAA181, Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Onitilo, Adedayo A
Plasma Cell, Bone Marrow
Adult
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Revels, Cheryl M
(715) 389-4177
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI  54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Neillsville
216 Sunset Place
Neillsville, Wi  54456
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476